IP Library › Granted Patent US 12,371,511
Granted Patent B2
US 12,371,511 · App. 15/860,163 · Granted Jul 29, 2025

Heterodimerized polypeptide

Inventors: Futa Mimoto (Shizuoka, JP); Taichi Kuramochi (Shizuoka, JP); Tomoyuki Igawa (Shizuoka, JP); Meiri Kawazoe (Shizuoka, JP); Hitoshi Katada (Shizuoka, JP); Hirotake Shiraiwa (Shizuoka, JP); Shojiro Kadono (Kanagawa, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha
C07K16/46C07K1/1075C07K16/00C07K16/18C07K16/22C07K16/2866C07K16/30C07K16/303C07K16/36G01N33/566C07K2317/52C07K2317/524C07K2317/71C07K2317/72C07K2317/732C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,371,511
App. No.
15/860,163
Granted
Jul 29, 2025
Kind
B2
Abstract

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.

Claims (160)

1. A molecule comprising a heterodimeric Fc region that is a heterodimer of a first Fc polypeptide and a second Fc polypeptide that differs in amino acid sequence from the first Fc polypeptide,

wherein the first Fc polypeptide comprises a hinge region or a part thereof, a first human IgG1 CH2 domain and a CH3 domain, wherein the first human IgG1 CH2 domain comprises a set of substitutions selected from sets (i) to (vi), and wherein all positions are by EU numbering:

(i) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of His at position 268 with Asp, Glu, or Ala, and

substitution of Ser at position 298 with Ala;

(ii) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of His at position 268 with Asp, Glu, or Ala,

substitution of Asp at position 270 with Glu, and

substitution of Ser at position 298 with Ala;

(iii) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of Ser at position 239 with Met,

substitution of His at position 268 with Asp, Glu, or Ala,

substitution of Asp at position 270 with Glu, and

substitution of Ser at position 298 with Ala;

(iv) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of His at position 268 with Asp, Glu, or Ala,

substitution of Ser at position 298 with Ala, and

substitution of Ala at position 327 with Asp;

(v) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of Ser at position 239 with Met,

substitution of His at position 268 with Asp, Glu, or Ala,

substitution of Ser at position 298 with Ala, and

substitution of Ala at position 327 with Asp;

(vi) substitution of Leu at position 234 with Tyr, Ala, Glu, Gly, His, or Ser,

substitution of Leu at position 235 with Tyr, Ala, Glu, Phe, Ile, Leu, Met, Asn, Pro, Gln, Thr, Val, or Trp,

substitution of Gly at position 236 with Trp or Tyr,

substitution of Ser at position 239 with Met,

substitution of His at position 268 with Asp, Glu, or Ala,

substitution of Ser at position 298 with Ala,

substitution of Ala at position 327 with Asp,

substitution of Leu at position 328 with Trp, and

substitution of Lys at position 334 with Ile, Glu, or Asp;

and wherein the second Fc polypeptide comprises a hinge region or a part thereof, a second human IgG1 CH2 domain and a CH3 domain, wherein the second human IgG1 CH2 domain comprises a set of substitutions selected from sets (vii) and (viii), and wherein all positions are by EU numbering:

(vii) substitution of Lys at position 326 with Thr, Asp, or Ile,

substitution of Ala at position 330 with Lys, Pro, Met, or Phe, and

substitution of Lys at position 334 with Ile, Glu, or Asp;

(viii) substitution of Asp at position 270 with Glu,

substitution of Lys at position 326 with Thr, Asp, or Ile,

substitution of Ala at position 330 with Lys, Pro, Met, or Phe, and

substitution of Lys at position 334 with Ile, Glu, or Asp.

2. The molecule of claim 1 , wherein the molecule is an antibody.

3. The molecule of claim 2 , wherein the antibody is a bispecific antibody.

4. The molecule of claim 1 , wherein the molecule is a peptide Fc fusion protein or a scaffold Fc fusion protein.

5. A pharmaceutical composition comprising the molecule of claim 1 and a medically acceptable carrier.

6. A method of producing the molecule of claim 1 , the method comprising:

identifying a parent molecule comprising an Fc region that is a homodimer of a starting polypeptide;

producing a first mutated version of the starting polypeptide, the first mutated version being the first polypeptide;

producing a second mutated version of the starting polypeptide, the second mutated version being the second polypeptide; and

generating the molecule comprising the heterodimeric Fc region that is a heterodimer of the first polypeptide and the second polypeptide.

7. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (i).

8. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (ii).

9. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iii).

10. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iv).

11. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (v).

12. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (vi).

13. The molecule of claim 1 , wherein the second human IgG1 CH2 domain comprises the substitutions of set (vii).

14. The molecule of claim 1 , wherein the second human IgG1 CH2 domain comprises the substitutions of set (viii).

15. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (i), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

16. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (i), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

17. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (ii), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

18. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (ii), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

19. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iii), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

20. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iii), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

21. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iv), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

22. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (iv), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

23. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (v), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

24. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (v), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

25. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (vi), and the second human IgG1 CH2 domain comprises the substitutions of set (vii).

26. The molecule of claim 1 , wherein the first human IgG1 CH2 domain comprises the substitutions of set (vi), and the second human IgG1 CH2 domain comprises the substitutions of set (viii).

27. The molecule of claim 1 , wherein the sequence of the first Fc polypeptide differs from the sequence of the second Fc polypeptide at one or more additional positions, and wherein at least one of the differences at the one or more additional positions confers or increases a difference in isoelectric points between the first and second Fc polypeptides.

28. The molecule of claim 27 , wherein at least one of the one or more additional positions in which a difference in sequence confers or increases a difference in isoelectric points is selected from the following group, wherein all positions are by EU numbering:

position 137,

position 138,

position 139,

position 147,

position 192,

position 193,

position 196,

position 198,

position 199,

position 203,

position 214,

position 263,

position 272,

position 274,

position 278,

position 288,

position 290,

position 316,

position 317,

position 320,

position 324,

position 335,

position 337,

position 340,

position 358,

position 360,

position 362,

position 364,

position 383,

position 384,

position 385,

position 386,

position 387,

position 390,

position 397, and

position 422.

29. The molecule of claim 1 , wherein

(a) the first Fc polypeptide comprises one or more additional substitutions, compared to a naturally occurring human IgG1 Fc, at one or more of the following EU numbering positions, and the one or more additional substitutions in the first polypeptide confers or increases a difference in isoelectric points between the first Fc polypeptide and the second Fc polypeptide:

position 196,

position 199,

position 263,

position 272,

position 316,

position 358,

position 364,

position 383,

position 387, and

position 397; and

(b) the second Fc polypeptide comprises one or more additional substitutions, compared to a naturally occurring human IgG1 Fc, at one or more of the following EU numbering positions, and the one or more additional substitutions in the second Fc polypeptide confers or increases a difference in isoelectric points between the first Fc polypeptide and the second Fc polypeptide:

position 137,

position 138,

position 139,

position 147,

position 192,

position 193,

position 198,

position 199,

position 203,

position 214,

position 274,

position 278,

position 288,

position 290,

position 316,

position 317,

position 320,

position 324,

position 335,

position 337,

position 340,

position 358,

position 360,

position 362,

position 383,

position 384,

position 385,

position 386,

position 390, and

position 422.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2018
From: MIMOTO, FUTA; KURAMOCHI, TAICHI; IGAWA, TOMOYUKI; KAWAZOE, MEIRI; KATADA, HITOSHI; SHIRAIWA, HIROTAKE; KADONO, SHOJIRO
To: CHUGAI SEIYAKU KABUSHIKI KAISHA
Reel/Frame 044521/0641 →
Priority Claims (2)
JP 2011-146778 · Jun 30, 2011 · national
JP 2011-288240 · Dec 28, 2011 · national
Continuity (2)
Continuation 14127576
Related Publication 20180155451A1 · Jun 7, 2018
References Cited (400)
US 6344443B1 · Liu et al. · 2002 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6852318B1 · Varner · 2005 [cited by applicant]
US 6946292B2 · Kanda et al. · 2005 [cited by applicant]
US 7229960B2 · Pero et al. · 2007 [cited by applicant]
US 7317091B2 · Lazar et al. · 2008 [cited by applicant]
US 7393531B2 · Young et al. · 2008 [cited by applicant]
US 7662925B2 · Lazar et al. · 2010 [cited by applicant]
US 7951917B1 · Arathoon · 2011 [cited by examiner]
US 7960512B2 · Stavenhagen et al. · 2011 [cited by applicant]
US 8101720B2 · Lazar et al. · 2012 [cited by applicant]
US 8524867B2 · Bernett et al. · 2013 [cited by applicant]
US 8685725B2 · Beliard et al. · 2014 [cited by applicant]
US 8735545B2 · Lazar et al. · 2014 [cited by applicant]
US 8802823B2 · Lazar et al. · 2014 [cited by applicant]
US 9017684B2 · Aburatani et al. · 2015 [cited by applicant]
US 9051373B2 · Lazar et al. · 2015 [cited by applicant]
US 9079949B1 · Andrien, Jr. et al. · 2015 [cited by applicant]
US 9107861B1 · Andrien, Jr. et al. · 2015 [cited by applicant]
US 9200060B2 · Kannan et al. · 2015 [cited by applicant]
US 9556264B2 · Shiraiwa et al. · 2017 [cited by applicant]
US 9890218B2 · Mimoto · 2018 [cited by examiner]
US 10196445B1 · Engelhardt et al. · 2019 [cited by applicant]
US 10766960B2 · Igawa et al. · 2020 [cited by applicant]
US 10919953B2 · Katada et al. · 2021 [cited by applicant]
US 11142563B2 · Igawa et al. · 2021 [cited by applicant]
US 11267868B2 · Mimoto et al. · 2022 [cited by applicant]
US 20040001822A1 · Levanon et al. · 2004 [cited by applicant]
US 20040001839A1 · Levanon et al. · 2004 [cited by applicant]
US 20040002450A1 · Lezarovits et al. · 2004 [cited by applicant]
US 20040110226A1 · Lazar et al. · 2004 [cited by applicant]
US 20050032114A1 · Hinton et al. · 2005 [cited by applicant]
US 20050260213A1 · Koenig et al. · 2005 [cited by applicant]
US 20060024298A1 · Lazar et al. · 2006 [cited by applicant]
US 20060074225A1 · Chamberlain et al. · 2006 [cited by applicant]
US 20060134709A1 · Stavenhagen et al. · 2006 [cited by applicant]
US 20060140934A1 · Gegg et al. · 2006 [cited by applicant]
US 20060275283A1 · Van Vlijmen et al. · 2006 [cited by applicant]
US 20070231329A1 · Lazar et al. · 2007 [cited by applicant]
US 20070248602A1 · Lazar et al. · 2007 [cited by applicant]
US 20080044417A1 · Johnson et al. · 2008 [cited by applicant]
US 20080051563A1 · Lazar et al. · 2008 [cited by applicant]
US 20080138349A1 · Stavenhagen et al. · 2008 [cited by applicant]
US 20080181890A1 · Lazar et al. · 2008 [cited by applicant]
US 20080199471A1 · Bernett et al. · 2008 [cited by applicant]
US 20090035836A1 · Datta et al. · 2009 [cited by applicant]
US 20090041770A1 · Chamberlain et al. · 2009 [cited by applicant]
US 20090053211A9 · Lazar et al. · 2009 [cited by applicant]
US 20090076251A1 · Koenig et al. · 2009 [cited by applicant]
US 20090136485A1 · Chu et al. · 2009 [cited by applicant]
US 20100098730A1 · Lowman et al. · 2010 [cited by applicant]
US 20100184959A1 · Guler-Gane et al. · 2010 [cited by applicant]
US 20100249482A1 · Chung et al. · 2010 [cited by applicant]
US 20100286374A1 · Kannan et al. · 2010 [cited by applicant]
US 20100316641A1 · Dimitrov · 2010 [cited by applicant]
US 20100331527A1 · Davis et al. · 2010 [cited by applicant]
US 20110021755A1 · Lazar et al. · 2011 [cited by applicant]
US 20110027276A1 · Bernett et al. · 2011 [cited by applicant]
US 20110111406A1 · Igawa et al. · 2011 [cited by applicant]
US 20110223658A1 · Beliard et al. · 2011 [cited by applicant]
US 20110229489A1 · Pons et al. · 2011 [cited by applicant]
US 20120009188A1 · Behrens et al. · 2012 [cited by applicant]
US 20120093818A1 · Jackson et al. · 2012 [cited by applicant]
US 20120149876A1 · Von Kreudenstein · 2012 [cited by examiner]
US 20120244578A1 · Kannan · 2012 [cited by examiner]
US 20130085265A1 · Jackson et al. · 2013 [cited by applicant]
US 20130101581A1 · Kuramochi et al. · 2013 [cited by applicant]
US 20130131319A1 · Igawa et al. · 2013 [cited by applicant]
US 20130209457A1 · Lazar et al. · 2013 [cited by applicant]
US 20130247234A1 · McWhirter et al. · 2013 [cited by applicant]
US 20130259876A1 · Murphy et al. · 2013 [cited by applicant]
US 20140044730A1 · Yancopoulos et al. · 2014 [cited by applicant]
US 20140082760A1 · McWhirter et al. · 2014 [cited by applicant]
US 20140093496A1 · Mimoto et al. · 2014 [cited by applicant]
US 20140105889A1 · Igawa et al. · 2014 [cited by applicant]
US 20140112914A1 · Nezu et al. · 2014 [cited by applicant]
US 20140112926A1 · Liu · 2014 [cited by applicant]
US 20140234340A1 · Igawa et al. · 2014 [cited by applicant]
US 20140335089A1 · Igawa et al. · 2014 [cited by applicant]
US 20140356371A1 · Swergold et al. · 2014 [cited by applicant]
US 20150166636A1 · Igawa et al. · 2015 [cited by applicant]
US 20150166654A1 · Igawa et al. · 2015 [cited by applicant]
US 20150203577A1 · Igawa et al. · 2015 [cited by applicant]
US 20150252107A1 · Stevis et al. · 2015 [cited by applicant]
US 20150299296A1 · Katada et al. · 2015 [cited by applicant]
US 20150299313A1 · Igawa et al. · 2015 [cited by applicant]
US 20150344570A1 · Igawa et al. · 2015 [cited by applicant]
US 20150353630A1 · Igawa et al. · 2015 [cited by applicant]
US 20160039912A1 · Mimoto et al. · 2016 [cited by applicant]
US 20160046693A1 · Igawa et al. · 2016 [cited by applicant]
US 20160159904A1 · Yamazaki et al. · 2016 [cited by applicant]
US 20160200807A1 · Ruike et al. · 2016 [cited by applicant]
US 20160229915A1 · Igawa et al. · 2016 [cited by applicant]
US 20170129950A1 · Shiraiwa et al. · 2017 [cited by applicant]
US 20180258161A1 · Igawa et al. · 2018 [cited by applicant]
US 20190112393A1 · Igawa et al. · 2019 [cited by applicant]
US 20200181257A1 · Kuramochi et al. · 2020 [cited by applicant]
US 20210261648A1 · Katada et al. · 2021 [cited by applicant]
US 20220242934A1 · Igawa et al. · 2022 [cited by applicant]
US 20220389118A1 · Igawa et al. · 2022 [cited by applicant]
US 20220411483A1 · Mimoto et al. · 2022 [cited by applicant]
US 20230020377A1 · Katada et al. · 2023 [cited by applicant]
US 20230416371A1 · Katada et al. · 2023 [cited by applicant]
US 20240043515A1 · Katada et al. · 2024 [cited by applicant]
AU 2012222252 · 2013 [cited by applicant]
CA 2815266 · 2012 [cited by applicant]
CA 2827923 · 2012 [cited by applicant]
CN 1291198 · 2001 [cited by applicant]
CN 1763097 · 2006 [cited by applicant]
CN 101001873 · 2007 [cited by applicant]
CN 101014619 · 2007 [cited by applicant]
CN 101932593 · 2010 [cited by applicant]
CN 102056946 · 2011 [cited by applicant]
CN 102149729 · 2011 [cited by applicant]
CN 103492565 · 2014 [cited by applicant]
CN 103827300 · 2014 [cited by applicant]
CN 102633880 · 2015 [cited by applicant]
EA 004317 · 2004 [cited by applicant]
EP 1537878A · 2005 [cited by applicant]
EP 2196541 · 2010 [cited by applicant]
EP 2275443 · 2011 [cited by applicant]
EP 2368911 · 2011 [cited by applicant]
EP 2409990A · 2012 [cited by applicant]
EP 2647706 · 2013 [cited by applicant]
EP 2679681 · 2014 [cited by applicant]
EP 2698431 · 2014 [cited by applicant]
EP 2728002 · 2014 [cited by applicant]
EP 2762166 · 2014 [cited by applicant]
EP 2765192A · 2014 [cited by applicant]
EP 2818183A · 2014 [cited by applicant]
EP 2889377 · 2015 [cited by applicant]
EP 2940135 · 2015 [cited by applicant]
EP 3586872A · 2020 [cited by applicant]
JP 2003512019 · 2003 [cited by applicant]
JP 2006512407 · 2006 [cited by applicant]
JP 2006524039 · 2006 [cited by applicant]
JP 2007532139 · 2007 [cited by applicant]
JP 2008505174 · 2008 [cited by applicant]
JP 2008511292 · 2008 [cited by applicant]
JP 2008514201 · 2008 [cited by applicant]
JP 2009511067 · 2009 [cited by applicant]
JP 2009511587 · 2009 [cited by applicant]
JP 2009538273 · 2009 [cited by applicant]
JP 2009540837 · 2009 [cited by applicant]
JP 2010514460 · 2010 [cited by applicant]
JP 2014509857 · 2014 [cited by applicant]
JP 2014528906 · 2014 [cited by applicant]
JP 6433297 · 2018 [cited by applicant]
JP 6628966 · 2020 [cited by applicant]
JP 2020040975 · 2020 [cited by applicant]
JP 2020073557 · 2020 [cited by applicant]
JP 2021511812 · 2021 [cited by applicant]
KR 20110004435 · 2011 [cited by applicant]
RU 2236222 · 2004 [cited by applicant]
RU 2005112742 · 2006 [cited by applicant]
RU 2006142852 · 2008 [cited by applicant]
RU 2337107 · 2008 [cited by applicant]
RU 2390527 · 2010 [cited by applicant]
RU 2398777 · 2010 [cited by applicant]
SG 192945 · 2013 [cited by applicant]
TW 201116625 · 2011 [cited by applicant]
TW 201202419 · 2012 [cited by applicant]
WO WO9514714 · 1995 [cited by applicant]
WO WO9734631 · 1997 [cited by applicant]
WO WO9940117 · 1999 [cited by applicant]
WO WO9958572 · 1999 [cited by applicant]
WO WO0015214 · 2000 [cited by applicant]
WO WO0037504 · 2000 [cited by applicant]
WO WO0042072 · 2000 [cited by applicant]
WO WO0114424 · 2001 [cited by applicant]
WO WO0170968 · 2001 [cited by applicant]
WO WO2002079255 · 2002 [cited by applicant]
WO WO2004004771 · 2004 [cited by applicant]
WO WO2004029207 · 2004 [cited by applicant]
WO WO2004063351 · 2004 [cited by applicant]
WO WO2004099249 · 2004 [cited by applicant]
WO WO2005003298 · 2005 [cited by applicant]
WO WO2005047327 · 2005 [cited by applicant]
WO WO2005056606 · 2005 [cited by applicant]
WO WO2005059106 · 2005 [cited by applicant]
WO WO2005115452 · 2005 [cited by applicant]
WO WO2006015371 · 2006 [cited by applicant]
WO WO2006019447 · 2006 [cited by applicant]
WO WO2006020114 · 2006 [cited by applicant]
WO WO2006023403 · 2006 [cited by applicant]
WO WO2006023420 · 2006 [cited by applicant]
WO WO2006036291 · 2006 [cited by applicant]
WO WO2006036834 · 2006 [cited by applicant]
WO WO2006072620 · 2006 [cited by applicant]
WO WO2006076594 · 2006 [cited by applicant]
WO WO2006083706 · 2006 [cited by applicant]
WO WO2006085938 · 2006 [cited by applicant]
WO WO2006088494 · 2006 [cited by applicant]
WO WO2006106905 · 2006 [cited by applicant]
WO WO2006130834 · 2006 [cited by applicant]
WO WO2006133486 · 2006 [cited by applicant]
WO WO2007022520 · 2007 [cited by applicant]
WO WO2007024249 · 2007 [cited by applicant]
WO WO2007047291 · 2007 [cited by applicant]
WO WO2007047578 · 2007 [cited by applicant]
WO WO2007114325 · 2007 [cited by applicant]
WO WO2007121354 · 2007 [cited by applicant]
WO WO2008002933 · 2008 [cited by applicant]
WO WO2008003103 · 2008 [cited by applicant]
WO WO2008091954 · 2008 [cited by applicant]
WO WO2008150494 · 2008 [cited by applicant]
WO WO2009041062 · 2009 [cited by applicant]
WO WO2009062083 · 2009 [cited by applicant]
WO WO2009095235 · 2009 [cited by applicant]
WO WO2009125825 · 2009 [cited by applicant]
WO WO2009131702 · 2009 [cited by applicant]
WO WO2009139822 · 2009 [cited by applicant]
WO WO2009155513 · 2009 [cited by applicant]
WO WO2010058860 · 2010 [cited by applicant]
WO WO2010077854 · 2010 [cited by applicant]
WO WO2010085682 · 2010 [cited by applicant]
WO WO2010107109 · 2010 [cited by applicant]
WO WO2011008517 · 2011 [cited by applicant]
WO WO2011091078 · 2011 [cited by applicant]
WO WO2011107989 · 2011 [cited by applicant]
WO WO2011108714 · 2011 [cited by applicant]
WO WO2011111007 · 2011 [cited by applicant]
WO WO2011122011 · 2011 [cited by applicant]
WO WO2012032080 · 2012 [cited by applicant]
WO WO2012044831 · 2012 [cited by applicant]
WO WO2012058768 · 2012 [cited by applicant]
WO WO2012073985 · 2012 [cited by applicant]
WO WO2012073992 · 2012 [cited by applicant]
WO WO2012115241 · 2012 [cited by applicant]
WO WO2012120125 · 2012 [cited by applicant]
WO WO2012125850 · 2012 [cited by applicant]
WO WO2012132067 · 2012 [cited by applicant]
WO WO2012133782 · 2012 [cited by applicant]
WO WO2013002362 · 2013 [cited by applicant]
WO WO2013046704 · 2013 [cited by applicant]
WO WO2013047729 · 2013 [cited by applicant]
WO WO2013047748 · 2013 [cited by applicant]
WO WO2013047752 · 2013 [cited by applicant]
WO WO2013063702 · 2013 [cited by applicant]
WO WO2013100120 · 2013 [cited by applicant]
WO WO2013118858 · 2013 [cited by applicant]
WO WO2013125667 · 2013 [cited by applicant]
WO WO2013138681 · 2013 [cited by applicant]
WO WO2013180200 · 2013 [cited by applicant]
WO WO2013187495 · 2013 [cited by applicant]
WO WO2014030728 · 2014 [cited by applicant]
WO WO2014104165 · 2014 [cited by applicant]
WO WO2014140366 · 2014 [cited by applicant]
WO WO2014144080 · 2014 [cited by applicant]
WO WO2014144577 · 2014 [cited by applicant]
WO WO2014150983 · 2014 [cited by applicant]
WO WO2014163101 · 2014 [cited by applicant]
WO WO2014164959 · 2014 [cited by applicant]
WO WO2014177459A2 · 2014 [cited by applicant]
WO WO2015042250 · 2015 [cited by applicant]
WO WO2015077491 · 2015 [cited by applicant]
WO WO2015083764 · 2015 [cited by applicant]
WO WO2015134894 · 2015 [cited by applicant]
WO WO2016196237 · 2016 [cited by applicant]
WO WO2018155611 · 2018 [cited by applicant]
WO WO2019152413 · 2019 [cited by applicant]
WO WO2020014413 · 2020 [cited by applicant]
WO WO2021131021 · 2021 [cited by applicant]
WO WO2022044248A1 · 2022 [cited by applicant]
WO WO2022045276A1 · 2022 [cited by applicant]
U.S. Appl. No. 14/379,825, filed Aug. 20, 2014, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/377,556, filed Aug. 8, 2014, Kuramochi et al. [cited by applicant]
U.S. Appl. No. 14/406,232, filed Dec. 8, 2014, Igawa et al. [cited by applicant]
U.S. Appl. No. 14/423,269, filed Feb. 23, 2015, Katada et al. [cited by applicant]
Amigorena et al., “Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes,” Science, 256(5065):1808-12 (1992). [cited by applicant]
Amigorena et al., “Fc gamma RII expression in resting and activated B lymphocytes,” Eur J Immunol., (8):1379-85 (1989). [cited by applicant]
Armour et al., “Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies,” Mol Immunol., 40(9):585-93 (2003). [cited by applicant]
Atwell et al., “Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library,” J Mol Biol., Jul. 4, 1997;270(1):26-35. [cited by applicant]
Bjellqvist et al., “The focusing positions of polypeptides in immobilized pH gradients can be predicted from their amino acid sequences,” Electrophoresis. Jan. 1, 1993;14(1):1023-31. [cited by applicant]
Blank et al., Decreased transcription of the human FCGR2B gene mediated by the -343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet., Jul. 2005;117(2-3):220-7. Epub May 14, 2005. [cited by applicant]
Boruchov et al., “Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions,” J Clin Invest., Oct. 2005;115(10):2914-23. Epub Sep. 15, 2005. [cited by applicant]
Boumpas et al., “A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis,” Arthritis Rheum., 48(3):719-27 (2003). [cited by applicant]
Bruhns et al., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses, Blood, Apr. 16, 2009;113(16):3716-25. doi: 10.1182/blood-2008-09-179754. Epub Nov. 18, 2008. [cited by applicant]
Bruhns, “Properties of mouse and human IgG receptors and their contribution to disease models,” Blood, Jun. 14, 2012;119(24):5640-9. doi: 10.1182/blood-2012-01-380121. Epub Apr. 25, 2012. [cited by applicant]
Burmeister et al., “Crystal structure of the complex of rat neonatal Fc receptor with Fc,” Nature, Nov. 24, 1994;372(6504):379-83. [cited by applicant]
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene,” Blood, Feb. 1, 2002;99(3):754-8. [cited by applicant]
Cemerski et al., “Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb,” Immunol Lett., Mar. 30, 2012;143(1):34-43. doi: 10.1… [cited by applicant]
Chan et al., “Therapeutic antibodies for autoimmunity and inflammation,” Nat Rev Immunol., May 2010;10(5):301-16. doi: 10.1038/nri2761. [cited by applicant]
Chen et al., “Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients,” Arthritis Rheum., 54(12):3908-17 (2006). [cited by applicant]
Chu et al., “Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcgammaRIIb with Fc-engineered antibodies,” Mol Immunol., Sep. 2008;45(15):3926-33. doi: 10.1016/j.moli… [cited by applicant]
Chu et al., “Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody,” J Allergy Clin Immunol., Apr. 2012; 129(4):1102-15. doi: 10.1016/j.jaci.2011.11.029. Epub Jan… [cited by applicant]
Chuntharapai et al., “Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4,” J Immunol., 166(8):4891-8 (2001). [cited by applicant]
Clark, “IgG effector mechanisms,” Chem Immunol., 1997;65:88-110. [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci USA, Jan. 20, 1998;95(2):652-6. [cited by applicant]
Clynes et al., “Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets,” Nat Med., Apr. 2000;6(4):443-6. [cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” Res. Immunol., Dec. 1994. 31; 145(1):33-36. [cited by applicant]
Dall'Acqua et al., “Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences,” J. Immunol., 169(9):5171-80 (2002). [cited by applicant]
Datta-Mannan et al., “Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor,” J Biol Chem., Jan. 19, 2007;282(3):1709-17. Epub Nov. 29, 2006. [cited by applicant]
Davis et al., “Seedbodies: fusion proteins based on strand-exchange engineered domain (Seed) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies,” Protein Eng De… [cited by applicant]
Desai et al., “Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses,” J Immunol., 178(10):6217-26 (2007). [cited by applicant]
Dhodapkar et al., “Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells,” Proc Natl Acad Sci USA, Feb. 22, 2005;1… [cited by applicant]
Duffau et al., “Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus,” Sci Transl Med., Sep. 1, 2010;2(47):47ra63. doi: 10.1126/scitranslmed.3001001. [cited by applicant]
Edelman et al., “The covalent structure of an entire gammaG immunoglobulin molecule,” Proc Natl Acad Sci U S A., May 1969;63(1):78-85. [cited by applicant]
Floto et al., “Loss of function of a lupus-associated FcgammaRIIb polymorphism through exclusion from lipid rafts,” Nat Med., Oct. 2005;11(10):1056-8. Epub Sep. 18, 2005. [cited by applicant]
Fournier et al., “Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB,” J Immunol., Oct. 15, 2008;181(8):5350-9. [cited by applicant]
Ghetie et al., “Increasing the serum persistence of an IgG fragment by random mutagenesis,” Nat. Biotechnol., 15(7):637-40 (1997). [cited by applicant]
Greenwood et al., “Structural motifs involved in human IgG antibody effector functions,” Eur J Immunol., May 1993;23(5):1098-104. [cited by applicant]
Guilliams et al., “The function of Fcy receptors in dendritic cells and macrophages,” Nat Rev Immunol., Feb. 2014;14(2):94-108. doi: 10.1038/nri3582. Epub Jan. 21, 2014. [cited by applicant]
Gunasekaran et al., “Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” J Biol Chem., 285(25):19637-46 (2010). [cited by applicant]
Hanson et al., “Catalytic antibodies and their applications,” Curr. Opin. Biotechnol., Dec. 2005; 16(6):631-6. Epub Oct. 21, 2005. [cited by applicant]
Hess et al., “Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity,” Future Oncol., Jan. 2012;8(1):73-85. doi: 10.2217/fon.11.138. [cited by applicant]
Heyman, “Feedback regulation by IgG antibodies,” Immunol Lett., 88(2):157-61 (2003). [cited by applicant]
Hinton et al., “An engineered human IgG1 antibody with longer serum half-life,” J. Immunol., 176(1):346-56 (2006). [cited by applicant]
Hjelm et al., “Antibody-mediated regulation of the immune response,” Scand J Immunol., Sep. 2006;64(3):177-84. [cited by applicant]
Horton et al., “Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia,” Cancer Res., Oct. 1, 2008;68(19):8049-57. doi: 10.1158/0008-5472. CAN-08-2268. [cited by applicant]
Idusogie et al., “Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc,” J Immunol., Apr. 15, 2000;164(8):4178-84. [cited by applicant]
Idusogie et al., “Engineered antibodies with increased activity to recruit complement,” J Immunol., Feb. 15, 2001;166(4):2571-5. [cited by applicant]
Igawa et al., “Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization,” Nat Biotechnol., Nov. 2010;28(11):1203-7. doi: 10.1038/nbt.1691. Epub Oct. 17, 2010. [cited by applicant]
Igawa et al., “Antibody Optimization Technologies for Developing Next Generation Antibody Therapeutics,” Bio Industry, 28(7):15-21 (2011) (with English translation). [cited by applicant]
IMGT Scientific Chart (Correspondence between the IMGT unique numbering for C-Domain, the IMGT exon numbering, the Eu and Kabat numberings: Human IGH G), [online] http://www.imgt.org/IMGTScientificChart/Numbering/Hu_IGH… [cited by applicant]
Information Meeting on Antibody Engineering Technologies, Copyright © Chugai Pharmaceutical Co., Ltd., Dec. 18, 2012. [cited by applicant]
Ito et al., “The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values,” FEBS Lett., 309:85-88 (199… [cited by applicant]
Jefferis et al., “Interaction sites on human IgG-Fc for Fc gamma R: current models,” Immunol Lett., Jun. 3, 2002;82(1-2):57-65. [cited by applicant]
Jones et al., “Growth factor receptor interplay and resistance in cancer,” Endocr Relat Cancer, Dec. 2006; 13 Suppl 1:S45-51. [cited by applicant]
Kim et al., “Antibody Engineering for the Development of Therapeutic Antibodies,” Mol. Cells, 20(1):17-29 (2005). [cited by applicant]
Kohrt et al., “Stimulation of natural killer cells with a CD 137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer,” J Clin Invest., Mar. 1, 2012;122(3):1066-75. doi: 10.1172/JCI6… [cited by applicant]
Kontermann, “Dual targeting strategies with bispecific antibodies,” MAbs., Mar.-Apr. 2012;4(2):182-97. doi: 10.4161/mabs.4.2.19000. Epub Mar. 1, 2012. [cited by applicant]
Lazar et al., “Engineered antibody Fc variants with enhanced effector function,” Proc Natl Acad Sci USA, Mar. 2006; 103(11):4005-10. Epub Mar. 6, 2006. [cited by applicant]
Li et al., “Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement,” Proc Natl Acad Sci U S A., Jul. 3, 2012;109(27):10966-71. doi: 10.1073/pnas.1208698109. Epub Jun. 20… [cited by applicant]
Li et al., “CD72 down-modulates BCR-induced signal transduction and diminishes survival in primary mature B lymphocytes,” J Immunol., 176(9):5321-8 (2006). [cited by applicant]
Li et al., “Inhibitory Fcγ receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies,” Science, Aug. 19, 2011;333(6045):1030-4. doi: 10.1126/science.1206954. [cited by applicant]
Liu et al., “Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies,” J Biol Chem., Feb. 7, 2014;289(6):3571-90. doi: 10.1… [cited by applicant]
Mackay et al., “Selective dysregulation of the FcgammaIIB receptor on memory B cells in SLE,” J Exp Med., Sep. 4, 2006;203(9):2157-64. Epub Aug. 21, 2006. [cited by applicant]
Malbec et al., “Antibodies against growth factor receptors can inhibit the proliferation of transformed cells via a cis-interaction with inhibitory FcR,” Immunol Lett., Mar. 30, 2012;143(1):28-33. [cited by applicant]
Manger et al., “Fcgamma receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms,” Arthritis Rheum., 41(7):1181-9 (1998). [cited by applicant]
Marino et al., “Prevention of systemic lupus erythematosus in MRL/lpr mice by administration of an immunoglobulin-binding peptide,” Nat Biotechnol., Jul. 2000;18(7):735-9. [cited by applicant]
Marvin et al., “Recombinant approaches to IgG-like bispecific antibodies,” Acta Pharmacol Sin., Jun. 2005;26(6):649-58. [cited by applicant]
Matsumiya et al., “Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1,” J Mol Biol., May 4, 2007;368(3):767-79. Epub Feb. 22, 2007. [cited by applicant]
Maurer et al., “Antigenicity of polypeptides (poly alpha amino acids): calcium-dependent and independent antibodies,” J Immunol., Sep. 1970; 105(3):567-73. [cited by applicant]
Maxfield et al., “Endocytic Recycling, ” Nat Rev Mol Cell Biol, Feb. 2004; 5(2):121-132. [cited by applicant]
Meyer et al., “Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice,” J Thromb Haemost., Jan. 2009;7(1):171-81. Epub Oct. 30, 2008. [cited by applicant]
Mi et al., “Targeting the neonatal fc receptor for antigen delivery using engineered fc fragments,” J Immunol., Dec. 1, 2008;181(11):7550-61. [cited by applicant]
Mimoto et al., “Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131),” Protein Eng Des Sel., Oct. 2013;26(10):589-98. doi: 10.1093/protein/gzt022. Epub Jun. … [cited by applicant]
Mimoto et al., “Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant,” MAbs., Mar.-Apr. 2013;5(2):229-36. doi: 10.4161/mabs.23452.… [cited by applicant]
Moore et al., “Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions,” MAbs., Mar.-Apr. 2010;2(2):181-9. [cited by applicant]
Morgan et al., “The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for Clq, Fc gamma RI and Fc gamma RIII binding,” Immunology, Oct. 1995; 86(2):319-24. [cited by applicant]
Muta et al., “A 13-amino-acid motif in the cytoplasmic domain of Fc gamma RIIB modulates B-cell receptor signaling,” Nature,368(6466):70-3 (1994). [cited by applicant]
Nakamura et al., “Fcgamma receptor IIB-deficient mice develop Goodpasture's syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease,” J Exp Med., Mar. 6… [cited by applicant]
Natsume et al., “Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities,” Cancer Res., May 15, 2008;68(10):3863-72. doi: 10.1158/0008-5472.CAN-07-6297. [cited by applicant]
Nicholas et al., “Regulation of the immune response. I. Reduction in ability of specific antibody to inhibit long-lasting IgG immunological priming after removal of the Fc fragment,” J Exp Med., 129(6):1183-201 (1969). [cited by applicant]
Nimmerjahn et al., “Divergent immunoglobulin g subclass activity through selective Fc receptor binding,” Science, Dec. 2, 2005;310(5753):1510-2. [cited by applicant]
Nimmerjahn et al., “Fcgamma receptors as regulators of immune responses,” Nat Rev Immunol., Jan. 2008;8(1):34-47. [cited by applicant]
Okabe, “Proprietary Innovative Antibody Engineering Technologies in Chugai Pharmaceutical,” Information meeting on Antibody Engineering Technologies, Dec. 18, 2012. [cited by applicant]
Olferiev et al., “The role of activating protein 1 in the transcriptional regulation of the human FCGR2B promoter mediated by the -343 G -> C polymorphism associated with systemic lupus erythematosus,” J Biol Chem., Jan… [cited by applicant]
Pavlou et al., “The therapeutic antibodies market to 2008,” Eur J Pharm Biopharm., Apr. 2005;59(3):389-96. [cited by applicant]
Meulenbroek et al., “Properties of human IgG subclasses,” Chapter 2.3 of Human IgG Subclasses: Useful Diagnostic Markers for Immunocompetence, published online by Sanquin, Amsterdam, The Netherlands. Retrieved from the … [cited by applicant]
Radaev et al., “The role of Fc glycosylation and the binding of peptide inhibitors,” J Biol Chem., May 11, 2001;276(19):16478-83. Epub Jan. 31, 2001. [cited by applicant]
Radaev et al., “The structure of a human type III Fcgamma receptor in complex with Fc,” J Biol Chem., May 11, 2001;276(19):16469-77. Epub Jan. 31, 2001. [cited by applicant]
Rajpal et al., A general method for greatly improving the affinity of antibodies by using combinatorial libraries, Proc. Natl. Acad. Sci. USA, Jun. 14, 2005;102(24):8466-71. Epub Jun. 6, 2005. [cited by applicant]
Rathanaswami et al., “Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8,” Biochem. Biophys. Res. Commun., 334(4):1004-13 (2005). [cited by applicant]
Ravetch et al., “Immune inhibitory receptors,” Science, 290(5489):84-9 (2000). [cited by applicant]
Reichert et al., “Monoclonal antibody successes in the clinic,” Nat Biotechnol., Sep. 2005;23(9):1073-8. [cited by applicant]
Reverberi et al., “Factors affecting the antigen-antibody reaction,” Blood Transfus., Nov. 2007;5(4):227-40. doi: 10.2450/2007.0047-07. [cited by applicant]
Richards et al., “Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells,” Mol Cancer Ther., Aug. 2008;7(8):2517-27. doi: 10.1158/1535-7163.MCT-08-0201. [cited by applicant]
Riechelmann et al., “Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial,” Cancer Immunol Immunother., Sep. 2007;56(9):1397-406. Epub Feb. 2, 2007. [cited by applicant]
Robles-Carrillo et al., “Anti-CD40L immune complexes potently activate platelets in vitro and cause thrombosis in FCGR2A transgenic mice,” J Immunol., Aug. 1, 2010;185(3):1577-83. doi: 10.4049/jimmunol.0903888. Epub Jun… [cited by applicant]
Rothe et al., “Recombinant proteins in rheumatology—recent advances,” N Biotechnol., Sep. 2011;28(5):502-10. doi: 10.1016/j.nbt.2011.03.019. Epub Apr. 5, 2011. [cited by applicant]
Rudikoff et al., “Single amino acid substitution altering antigen-binding specificity,” Proc Natl Acad Sci U S A., Mar. 1982;79(6):1979-83. [cited by applicant]
Salmon et al., “Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans,” J Clin Invest., 97(5):1348-54 (1996). [cited by applicant]
Samuelsson et al., “Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor,” Science, Jan. 19, 2001;291(5503):484-6. [cited by applicant]
Scappaticci et al., “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” J Natl Cancer Inst., Aug. 15, 2007;99(16): 1232-9. Epub Aug. 8, 2007. [cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev., Oct. 2010;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001… [cited by applicant]
Shields et al., “High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R,” J Biol Chem., Mar. … [cited by applicant]
Shinkawa et al., “The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cyt… [cited by applicant]
Siberil et al., “Molecular aspects of human FcgammaR interactions with IgG: functional and therapeutic consequences,” Immunol Lett., Aug. 15, 2006;106(2):111-8. Epub Jun. 12, 2006. [cited by applicant]
Smith et al., “FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications,” Nat Rev Immunol., May 2010;10(5):328-43. doi: 10.1038/nri2762. [cited by applicant]
Sondermann et al., “The 3.2—A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex,” Nature, Jul. 20, 2000;406(6793):267-73. [cited by applicant]
Stevenson et al., “A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge,” Anticancer Drug Des., Mar. 1989;3(4):219-30. [cited by applicant]
Su et al., Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus, J Immunol., 178(5):3272-80 (2007). [cited by applicant]
Suzuki et al., “Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion pro… [cited by applicant]
Traxlmayr et al., “Integrin binding human antibody constant domains—probing the C-terminal structural loops for grafting the RGD motif,” J Biotechnol., Sep. 10, 2011;155(2):193-202. doi: 10.1016/j.jbiotec.2011.06.042. E… [cited by applicant]
Unkeless et al., “Structure and function of human and murine receptors for IgG,” Annu Rev Immunol., 1988;6:251-81. [cited by applicant]
Veri et al., “Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIb (CD32B) from the activating Fcgamma-receptor IIa (CD32A): biochemical, biological and functional characterization,”… [cited by applicant]
Veri et al., “Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold,” Arthritis Rheum., Jul. 2010;62(7):1933-43. doi: 10.1… [cited by applicant]
Vidarsson et al., “IgG subclasses and allotypes: from structure to effector functions,” Front Immunol. Oct. 20, 2014;5:520. doi: 10.3389/fimmu.2014.00520. eCollection 2014. [cited by applicant]
Wang et al., “Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn Differentially with Pharmacokinetic Consequences,” Drug Metabolism and Disposition, Sep. 2011; 39(9):1469-77. [cited by applicant]
Warmerdam et al., Molecular basis for a polymorphism of human Fc gamma receptor II (CD32), Exp Med., 172(1):19-25 (1990). [cited by applicant]
Warncke et al., “Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment,” J Immunol. May 1, 2012 :188(9) :4405-11. doi: 10.4049/jimmunol. 120009… [cited by applicant]
Wenink et al., “The inhibitory Fc gamma IIb receptor dampens TLR4-mediated immune responses and is selectively up-regulated on dendritic cells from rheumatoid arthritis patients with quiescent disease,” J Immunol., Oct.… [cited by applicant]
Wernersson et al., “IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice,” J Immunol., 163(2):618-22 (1999). [cited by applicant]
Werwitzke et al., “Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32),” Ann Rheum Dis., Feb. 2008;67(2):154-61. Epub Jun. 8, 2007. [cited by applicant]
Wilson et al., “An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells,” Cancer Cell, Jan. 18, 2011;19(1):101-13. doi: 10.1016/j.ccr.2010.11.012. [cited by applicant]
Wozniak-Knopp et al., “Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties,” Protein Eng Des Sel., Apr. 2… [cited by applicant]
Xi et al., “Increased survival and reduced renal injury in MRL/lpr mice treated with a human Fcγ receptor II (CD32) peptide,” Immunology, May 2012;136(1):46-53. doi: 10.1111/j.1365-2567.2012.03553.x. [cited by applicant]
Xie et al., “A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis,” J Immunol Methods., Jan. 2005;296(1-2):95-101. Epub Nov. 19, 2004. [cited by applicant]
Wu et al., “Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract,” J. Mol. Biol., May 4, 2007;368(3):652-65. Epub Feb.… [cited by applicant]
Xu et al., “Fc gamma Rs modulate cytotoxicity of anti-Fas antibodies: implications for agonistic antibody-based therapeutics,” J Immunol., 171(2):562-8 (2003). [cited by applicant]
Yeung et al., “Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates,” J. Immunol., Jun. 15, 2009;182(12):7663-71. doi: 10.4049/jimmuno1.0804182. [cited by applicant]
Yuasa et al., “Deletion of fegamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis,” J Exp Med., 189(1):187-94 (1999). [cited by applicant]
Zalevsky et al., “The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates,” Blood, 113(16):3735-43 (2009). Epub Dec. 24, 2008. [cited by applicant]
Zalevsky et al., “Enhanced antibody half-life improves in vivo activity,” Nat Biotechnol., Feb. 2010;28(2):157-9. doi: 10.1038/nbt.1601. Epub Jan. 17, 2010. [cited by applicant]
Zeidler et al., Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing, J Immunol., Aug. 1, 1999;163(3):1246-52. [cited by applicant]
Zhang et al., “Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1,does not require activating Fc receptors,” Blood, Jul. 15, 2006;108(2):705-10. E… [cited by applicant]
Zhang et al., “Immune complex/Ig negatively regulate TLR4-triggered inflammatory response in macrophages through Fc gamma RIIb-dependent PGE2 production,” J Immunol., Jan. 1, 2009;182(1):554-62. [cited by applicant]
International Search Report for App. Ser. No. PCT/JP2013/084809, mailed Apr. 1, 2014, 4 pages. [cited by applicant]